359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community

Background

In particular, cancer patients with minor children encounter various problems, including family, parenting, employment, and economic burdens. This study aimed to examine the economic burden among cancer patients with minor children.

Methods

This was a sub-analysis of a cross-sectional web-based survey. Cancer patients with minor children were recruited from an online community and asked to answer a questionnaire.The proportion of subjects experiencing economic burden, and factors associated with economic burden were analyzed.

Results

A total of 368 subjects were eligible [19% male, mean age (SD): 43.0 years (5.8)]. The most common primary cancer site was breast (34%), followed by the colorectal region (12%), and gynecological organs (11%). Among the subjects, 127 (34%) experiencedeconomic burden. Univariate analyses showed that advanced stage (38% in subjects experiencing economic burden vs. 22% in subjects not experiencingeconomic burden, p = 0.002), presence of metastases (51% vs. 35%, p = 0.004), cancer recurrence (24% vs. 14%, p = 0.032), using anti-tumor drugs (47% vs. 33%, p = 0.010), having a full-time job (24% vs. 48%, p < 0.001), change of work situation (76% vs. 44%, p < 0.001), and decrease of income (76% vs. 38%, p < 0.001) were associated with patients experiencingeconomic burden.

Conclusions

The present study showed that advanced stage, anti-tumor treatment, and work situation were associated with economic burden among cancer patients with minor children.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

National Cancer Center.

Funding

Takeda Science Foundation.

Disclosure

K. Kosugi: Honoraria (self): Mundipharma. D. Fujisawa: Honoraria (self): Pfeizer, Mochida, Tanabe-Mitsubishi, Shionogi, Meiji Pharma, MSD. T. Kawaguchi: Honoraria (self): Chugai. K. Izumi: Full / Part-time employment: Medilead Inc. J. Takehana: Full / Part-time employment: Medilead Inc. Y. Matsumoto: Honoraria (self): Kyowa Kirin; Honoraria (self): Shionogi; Honoraria (self): Terumo; Honoraria (self): Meiji Seika Pharma; Honoraria (self): Hisamitsu Pharmaceutical; Honoraria (self): Eisai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self): Mundipharma; Honoraria (self): Daiichi-Sankyo. All other authors have declared no conflicts of interest.